US5019591A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for treating retinopathy and other small vessel disorders associated with diabetes
Assignee: Pennsylvania Research Corp
•
Filing: 1989-02-17
•
Granted: 1991-05-28
•
Expires: 2009-02-17
Abstract
Abstract A method for treating and preventing retinopathy and for treating and preventing other small vessel complications associated with diabetes which comprises administering a therapeutically effective amount of an antihistamine or a pharmaceutically acceptable derivative thereof to a mammal having retinopathy or other small vessel complications associated with diabetes.
Inventors
- 👤 Thomas W. Gardner
- 👤 Theodore M. Hollis
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-03 17:51
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/13; A61K31/135; A61K31/33; A61K31/335; A61K31/34
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
68 words
A method for treating and preventing retinopathy associated with diabetes which comprises administering a therapeutically effective amount of an antihistamine or a pharmaceutically acceptable derivative thereof to a mammal having retinopathy associated with diabetes, wherein the antihistamine is selected from the group consisting of diphenhydramine, terfenadine, mequitazine, astemizole, acrivastine, SCH 29851, SK&F 93944, clemastine, ketotifen, azatadine, oxatomide, azelastine, doxepine, piperoxan (933F), 929F, 1571F, mepyramine, chlorpheniramine, triprolidine and promethazine.
Claim 2
Independent Claim
68 words
A method for treating and preventing retinopathy associated with diabetes which comprises administering a therapeutically effective amount of an antihistamine or a pharmaceutically acceptable derivative thereof to a mammal having retinopathy associated with diabetes, wherein the antihistamine is selected from the group consisting of diphenhydramine, terfenadine, mequitazine, astemizole, acrivastine, SCH 29851, SK&F 93944, clemastine, ketotifen, azatadine, oxatomide, azelastine, doxepine, piperoxan (933F), 929F, 1571F, mepyramine, chlorpheniramine, triprolidine and promethazine.
Claim 3
Independent Claim
50 words
A method for treating and preventing retinopathy associated with diabetes which comprises administering a therapeutically effective amount of an antihistamine or a pharmaceutically acceptable derivative thereof to a mammal having retinopathy associated with diabetes, wherein the antihistamine is selected from the group consisting of burimamide, cimetidine, ranitidine, famotidine and nizatidine.
Claim 4
Independent Claim
50 words
A method for treating and preventing retinopathy associated with diabetes which comprises administering a therapeutically effective amount of an antihistamine or a pharmaceutically acceptable derivative thereof to a mammal having retinopathy associated with diabetes, wherein the antihistamine is selected from the group consisting of burimamide, cimetidine, ranitidine, famotidine and nizatidine.
Claim 5
Dependent Claim
12 words
A method as claimed in claim 1, wherein the antihistamine is diphenhydramine.
Claim 6
Dependent Claim
12 words
A method as claimed in claim 2, wherein the antihistamine is ranitidine.
Claim 7
Independent Claim
50 words
A method for treating and preventing retinopathy associated with diabetes which comprises administering a therapeutically effective amount of an antihistamine or a pharmaceutically acceptable derivative thereof to a mammal having retinopathy associated with diabetes, wherein the antihistamine is selected from the group consisting of diphenhydramine and ranitidine and mixtures thereof.
Claim 8
Independent Claim
50 words
A method for treating and preventing retinopathy associated with diabetes which comprises administering a therapeutically effective amount of an antihistamine or a pharmaceutically acceptable derivative thereof to a mammal having retinopathy associated with diabetes, wherein the antihistamine is selected from the group consisting of diphenhydramine and ranitidine and mixtures thereof.
Claim 9
Independent Claim
43 words
A method as claimed in claims 1, 2 or 5, wherein the therapeutically effective amount of the antihistamine is administered orally in the range of from about 5 mg/kg body mass to about 50 mg/kg body mass, from once to five times daily.
Claim 10
Dependent Claim
24 words
A method as claimed in claim 6, wherein the antihistamine or the pharmaceutically acceptable derivative thereof is administered orally in the form of tablets.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1994-05-27 | 1994-11-26 | 1995-05-28 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1998-05-27 | 1998-11-26 | 1999-05-28 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2002-05-27 | 2002-11-26 | 2003-05-28 | $7700.00 | Window Closed / Lapsed |